medigraphic.com
ISSN 0185-6014 (Impreso)
Órgano oficial de difusión de la Federación Mexicana de Patología Clínica, AC y de la Asociación Latinoamericana de Patología Clínica/Medicina de Laboratorio

2017, Número 3

<< Anterior Siguiente >>

Rev Mex Patol Clin Med Lab 2017; 64 (3)


Estudio de sensibilidad de fosfomicina en enterobacterias y microorganismos multidrogorresistentes de muestras de pacientes del Hospital General «Dr. Gaudencio González Garza» del CMN «La Raza»

Zamudio-Chávez O, Méndez-Tovar S, Apodaca-Tomas K, Cruz-Hernández M

Idioma: Español
Referencias bibliográficas: 26
Paginas: 114-119
Archivo PDF: 289.92 Kb.


RESUMEN

Introducción: El aumento constante de la resistencia microbiana es actualmente un problema a nivel mundial y ha llevado a muchos países a elaborar planes nacionales de control y a investigadores a diseñar nuevas estrategias terapéuticas para las infecciones. Objetivos: Conocer la sensibilidad a fosfomicina de las enterobacterias y microorganismos multidrogorresistentes aislados de diferentes especímenes de laboratorio. Material y métodos: Se realizó un estudio descriptivo analítico en donde se recolectaron 100 cepas, especialmente de la familia Enterobacteriaceae y otras multidrogorresistentes, aisladas de pacientes hospitalizados y de terapia ambulatoria; fueron identificadas por el sistema automatizado MALDI-TOF (bioMérieux) y VITEK 2XL; se sometieron a un reto de sensibilidad contra fosfomicina por el método de Kirby-Bauer. Resultados: Se identificaron 98% de cepas sensibles y 2% resistentes a este antibiótico. Conclusión: La fosfomicina puede considerarse como una opción terapéutica adecuada para enterobacterias y cepas multidrogorresistentes con base en la sensibilidad estudiada.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Martin D, Fougnot S, Grobost F, Thibaut-Jovelin S, Ballereau F, Gueudet T et al. Prevalence of extended-spectrum beta-lactamase producing Escherichia coli in community-onset urinary tract infections in France in 2013. J Infect. 2016; 72 (2): 201-206.

  2. Kahlmeter G, Poulsen HO. Antimicrobial susceptibility of Escherichia coli from community-acquired urinary tract infections in Europe: the ECO·SENS study revisited. Int J Antimicrob Agents. 2012; 39 (1): 45-51.

  3. Hendlin D, Stapley EO, Jackson M, Wallick H, Miller AK, Wolf FJ et al. Phosphonomycin, a new antibiotic produced by strains of streptomyces. Science. 1969; 166 (3901): 122-123.

  4. De Cueto M, Hernández JR, López-Cerero L, Morillo C, Pascual A. Actividad de fosfomicina sobre cepas de Escherichia coli y Klebsiella pneumoniae productoras de betalactamasas de espectro extendido. Enferm Infecc Microbiol Clin. 2006; 24 (10): 613-616.

  5. Kahan FM, Kahan JS, Cassidy PJ, Kropp H. The mechanism of action of fosfomycin (phosphonomycin). Ann N Y Acad Sci. 1974; 235 (0): 364-386.

  6. Kadner RJ, Winkler HH. Isolation and characterization of mutations affecting the transport of hexose phosphates in Escherichia coli. J Bacteriol. 1973; 113 (2): 895-900.

  7. Lu CL, Liu CY, Huang YT, Liao CH, Teng LJ, Turnidge JD et al. Antimicrobial susceptibilities of commonly encountered bacterial isolates to fosfomycin determined by agar dilution and disk diffusion methods. Antimicrob Agents Chemother. 2011; 55 (9): 4295-4301.

  8. Li Y, Zheng B, Li Y, Zhu S, Xue F, Liu J. Antimicrobial susceptibility and molecular mechanisms of fosfomycin resistance in clinical Escherichia coli isolates in mainland China. PLoS One. 2015; 10 (8): e0135269.

  9. Bergan T. Degree of absorption, pharmacokinetics of fosfomycin trometamol and duration of urinary antibacterial activity. Infection. 1990; 18 Suppl 2: S65-S69.

  10. Patel SS, Balfour JA, Bryson HM. Fosfomycin tromethamine. A review of its antibacterial activity, pharmacokinetic properties and therapeutic efficacy as a single-dose oral treatment for acute uncomplicated lower urinary tract infections. Drugs. 1997; 53 (4): 637-656.

  11. Yılmaz N, Ağuş N, Bayram A, Şamlıoğlu P, Şirin MC, Derici YK et al. Antimicrobial susceptibilities of Escherichia coli isolates as agents of community-acquired urinary tract infection (2008-2014). Turk J Urol. 2016; 42 (1): 32-36.

  12. Falagas ME, Maraki S, Karageorgopoulos DE, Kastoris AC, Kapaskelis A, Samonis G. Antimicrobial susceptibility of Gram-positive non-urinary isolates to fosfomycin. Int J Antimicrob Agents. 2010; 35 (5): 497-499.

  13. Bouchillon SK, Badal RE, Hoban DJ, Hawser SP. Antimicrobial susceptibility of inpatient urinary tract isolates of gram-negative bacilli in the United States: results from the study for monitoring antimicrobial resistance trends (SMART) program: 2009-2011. Clin Ther. 2013; 35 (6): 872-877.

  14. Neuner EA, Sekeres J, Hall GS, van Duin D. Experience with fosfomycin for treatment of urinary tract infections due to multidrug-resistant organisms. Antimicrob Agents Chemother. 2012; 56 (11): 5744-5748.

  15. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing; twenty-fifth informational supplement. Wayne, PA: 2015.

  16. Barry AL, Fuchs PC. In vitro susceptibility testing procedures for fosfomycin tromethamine. Antimicrob Agents Chemother. 1991; 35 (6): 1235-1238.

  17. Albur MS, Noel A, Bowker K, MacGowan A. The combination of colistin and fosfomycin is synergistic against NDM-1-producing Enterobacteriaceae in in vitro pharmacokinetic/pharmacodynamic model experiments. Int J Antimicrob Agents. 2015; 46 (5): 560-567.

  18. Yeganeh-Sefidan F, Ghotaslou R, Akhi MT, Sadeghi MR, Mohammadzadeh-Asl Y, Bannazadeh Baghi H. Fosfomycin, interesting alternative drug for treatment of urinary tract infections created by multiple drug resistant and extended spectrum β-lactamase producing strains. Iran J Microbiol. 2016; 8 (2): 125-131.

  19. Cağan Aktaş S, Gençer S, Batırel A, Hacıseyitoğlu D, Ozer S. Fosfomycin susceptibility of urinary Escherichia coli isolates producing extended-spectrum beta-lactamase according to CLSI and EUCAST recommendations. Mikrobiyol Bul. 2014; 48 (4): 545-555.

  20. Hirsch EB, Raux BR, Zucchi PC, Kim Y, McCoy C, Kirby JE et al. Activity of fosfomycin and comparison of several susceptibility testing methods against contemporary urine isolates. Int J Antimicrob Agents. 2015; 46 (6): 642-647.

  21. Okazaki M, Suzuki K, Asano N, Araki K, Shukuya N, Egami T et al. Effectiveness of fosfomycin combined with other antimicrobial agents against multidrug-resistant Pseudomonas aeruginosa isolates using the efficacy time index assay. J Infect Chemother. 2002; 8 (1): 37-42.

  22. Olay TA, Rodriguez A, Oliver LE, Vicente MV, Quecedo MC. Interaction of fosfomycin with other antimicrobial agents: in vitro and in vivo studies. J Antimicrob Chemother. 1978; 4 (6): 569-576.

  23. Hayami H, Goto T, Kawahara M, Ohi Y. Activities of beta-lactams, fluoroquinolones, amikacin and fosfomycin alone and in combination against Pseudomonas aeruginosa isolated from complicated urinary tract infections. J Infect Chemother. 1999; 5 (3): 130-138.

  24. Liu HY, Lin HC, Lin YC, Yu SH, Wu WH, Lee YJ. Antimicrobial susceptibilities of urinary extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae to fosfomycin and nitrofurantoin in a teaching hospital in Taiwan. J Microbiol Immunol Infect. 2011; 44 (5): 364-368.

  25. Sauget M, Valot B, Bertrand X, Hocquet D. Can MALDI-TOF mass spectrometry reasonably type bacteria? Trends Microbiol. 2017; 25 (6): 447-455.

  26. Rennie RP, Brosnikoff C, Shokoples S, Reller LB, Mirrett S, Janda W et al. Multicenter evaluation of the new Vitek 2 Neisseria-Haemophilus identification card. J Clin Microbiol. 2008; 46 (8): 2681-2685.




2020     |     www.medigraphic.com